The following securities that could potentially dilute basic net loss per share in the future were not included in the computation of diluted net loss per share for the periods presented, because to do so would have been antidilutive:


	Three and Six Months Ended June 30,
	2026		2025
Outstanding stock options		19,389,492		11,153,965
Outstanding restricted stock units		—		22,500
Common stock under employee stock purchase plan		542,312		—
Common stock warrants		21,308,618		161,616
Total		41,240,422		11,338,081

The table presented above does not include the number of shares that may be issued upon exercises of the common stock warrants issued in connection with the 2022 Convertible Notes and the 2023 Notes because the number of shares to be issued under these warrants are variable based on a variable exercise price at the warrant holders’ option.